Introduction

Mass torts have done more than produce headline settlements. They have reshaped how American civil litigation is investigated, financed, organized, and resolved. They have altered the evidentiary standards used to prove general causation, refined doctrines governing corporate responsibility, and accelerated procedural innovation across state and federal courts.

In formal terms, a mass tort is a civil action involving numerous plaintiffs who allege harm arising from a common product, practice, exposure, or catastrophic event, where claims retain individual characteristics such as injury type, causation, and damages. That last point matters. Unlike class actions, mass torts typically proceed through consolidated or coordinated structures while preserving individualized proof.

This article examines the mass torts that most decisively influenced the modern legal landscape, with particular attention to the procedural tools, scientific debates, and governance expectations they produced.

What “Modern” Means in Mass Tort Practice

Modern mass tort practice is defined by repeatable architecture:

• Consolidation and coordination, primarily through federal multidistrict litigation (MDL) under 28 U.S.C. § 1407 and state analogues in coordinated proceedings.
• Bellwether trials to test liability themes, scientific proof, and jury valuation.
• Plaintiff fact sheets and defense profiling to manage individualized data at scale.
• Science-driven causation battles, centered on epidemiology, toxicology, differential etiology, and expert admissibility under Daubert (federal) and state equivalents.
• Global settlement frameworks, frequently including lien resolution, claims matrices, future claims mechanisms, and supervision by settlement administrators and special masters.

The mass torts below did not merely fit inside that architecture. They helped build it.

For instance, the Dupixent Lawsuit, which involves numerous plaintiffs alleging harmful side effects from the drug Dupixent without adequate warnings from its manufacturers Sanofi and Regeneron. This lawsuit exemplifies how mass torts can arise from pharmaceutical products.

Similarly, the Zepbound vision loss lawsuits represents another significant instance of a mass tort. This lawsuit involves medication containing GLP-1 (glucagon-like peptide-1) receptor and GIP (glucose-dependent insulinotropic polypeptide) receptor, both of which are receptor agonists and are alleged to have caused thousands to suffered a myriad of server side effects including such as gastroparesis, persistent vomiting as well as severe vision problems including, most notably,  nonarteritic anterior ischemic optic neuropathy (NAION) which can lead to blindness and eventual death.

In another case of mass torts influencing the legal landscape is the Depo-Provera litigation which has been filed by thousands of women who were prescribed Depo-Provera and were subsequently diagnosed with Meningioma after suffering the brain tumor side effects of Depo-Prover and are are seeking compensation for their losses and pain and suffering alleging failed to warn of the risk of developing Meningioma.

These examples underline the significance of mass torts in shaping modern civil litigation practices in America.

Asbestos: The Most Influential Mass Tort in American Legal History

No mass tort has influenced American civil justice more than asbestos. What began as a workplace exposure story became a multi-decade restructuring of liability allocation, bankruptcy practice, and scientific proof.

Why it shaped the landscape:

• Latency and causation complexity. Diseases such as mesothelioma and asbestos have surfaced decades after exposure, forcing courts to manage stale evidence, shifting employment histories, and multiple potential sources of exposure.
• Joint and several liability pressures. Litigation highlighted the downstream effects of allocating fault among numerous suppliers, contractors, and premises owners.
• Bankruptcy trust innovation. A wave of insolvencies produced the modern asbestos trust system, where claims are paid through court-approved trusts funded by reorganized debtors.
• Case management at scale. Specialized asbestos dockets, consolidation practices, and trial groupings established templates later reused in other toxic torts.

Asbestos also accelerated a governance expectation that persists across industries: where risks are known or knowable, corporate systems must be capable of identifying, documenting, and controlling exposure pathways.

Tobacco Litigation: Causation, Marketing, and the Power of Internal Documents

Tobacco litigation, especially the state attorney general actions and major settlements, helped define modern strategies for proving corporate knowledge and public harm.

Lasting legal and strategic contributions

• Internal document discovery as a turning point. Corporate communications, research files, and marketing strategy became central evidentiary assets.
• Public health framing. Cases advanced arguments connecting product design, addiction science, and targeted marketing to population-level harms.
• Settlement as policy mechanism. Large-scale agreements demonstrated how negotiated resolutions can shape advertising restrictions, funding obligations, and compliance monitoring.

For corporate governance, tobacco litigation reinforced a repeated lesson: public-facing assurances must align with internal risk assessments, and compliance programs must withstand document-level scrutiny.

In addition to tort litigation like asbestos and tobacco cases, securities litigation also plays a significant role in shaping legal landscapes. It involves various stages of litigation with key players that include investors who have suffered losses due to misleading information or corporate fraud.

For instance, the Perrigo class action lawsuit is a notable example of securities litigation where shareholders alleged that false statements artificially inflated stock prices until the truth was revealed. Similarly, the Firefly Aerospace class action lawsuit serves as an instructive guide for investors involved in class action lawsuits against companies like Firefly Aerospace Inc.

Moreover, corporate governance issues often arise from these cases. This is where the experience of a Nashville whistleblower lawyer becomes crucial. Such lawyers play an essential role in protecting whistleblowers who expose corporate misconduct.

Lastly, it’s important to note that shareholders’ rights are not always upheld in

Agent Orange: Scientific Uncertainty and Veterans’ Claims

Agent Orange litigation highlighted how courts and policymakers respond when science is evolving and exposure histories are difficult to reconstruct.

What it changed

• Causation standards under uncertainty. Courts faced disputes where epidemiologic signals, mechanistic plausibility, and exposure confirmation did not neatly align.
• Administrative and legislative alternatives. The litigation era influenced later benefits frameworks and presumptions for veterans, illustrating that mass harm problems often spill beyond tort doctrine.

Agent Orange helped normalize the idea that complex injuries require hybrid approaches, blending litigation, benefits systems, and negotiated funds.

Silicone Breast Implants: Expert Evidence and the Evolution of Gatekeeping

Breast implant litigation is inseparable from modern expert admissibility. Battles over autoimmune claims and systemic injury theories elevated the role of epidemiology and rigorous expert methodology.

Impact on modern practice

• Expert screening and methodology scrutiny. Courts became more attentive to testability, error rates, peer review, and the distinction between association and causation.
• MDL experimentation. Coordinated proceedings used common discovery and structured evaluations to handle scientific disputes consistently.
• Settlement dynamics. The litigation demonstrated how settlement structures can collapse if claim volumes and injury valuations deviate from assumptions, reinforcing the importance of actuarial rigor.

A forward-looking takeaway is clear: as science-based products proliferate, corporate risk management must anticipate that scientific claims will be litigated through methodological credibility, not only through narrative persuasion.

Emerging Legal Challenges: Zepbound Eye Issues and Skye Bioscience Class Action

New scientific research continues to uncover troubling associations between certain products and serious health issues. For example, recent studies published in JAMA Ophthalmology have established a concerning association between GLP-1 receptor agonists, including those produced by companies like Skye Bioscience. This has led to a class action lawsuit against Skye Bioscience, seeking to represent purchasers or acquirers of their products.

As these cases illustrate, the intersection of evolving science and legal accountability is becoming increasingly complex. Just as with the Agent Orange or silicone breast implant litigation, these new legal challenges will require a nuanced understanding of scientific evidence in order to navigate effectively.

Firestone/Explorer Tire Litigation: Defect Theories and Recall Evidence

The Firestone tire controversy reinforced how product defect theories interact with recall data, engineering analysis, and fleet-level incident patterns.

Notable legal lessons

• Design and manufacturing defect differentiation. Litigants relied heavily on failure analysis, alternative design feasibility, and warning adequacy.
• Regulatory and recall records as evidence. Communications with regulators and recall decision-making became central in establishing knowledge and response timeliness.
• Coordinated proceedings maturity. Courts refined discovery protocols and early case vetting to reduce noise and improve trial readiness.

This mass tort contributed to a corporate governance expectation of traceability: design changes, quality assurance metrics, and field performance monitoring must be documented and operational, not aspirational.

The BP Deepwater Horizon Oil Spill: Corporate Safety Systems on Trial

Deepwater Horizon brought catastrophic tort litigation into contact with enterprise risk management, contractor oversight, and operational safety culture.

Why it matters to the modern landscape

• Complex multi-party allocation. Liability questions involved operators, contractors, subcontractors, and equipment manufacturers.
• Economic loss and environmental damages. Claims spanned personal injury, property damage, business interruption, and public resource impacts.
• Settlement administration at scale. The case advanced high-volume claims processing methods, documentation standards, and dispute resolution pathways.

The broader legacy is governance-driven: safety is not merely a regulatory checkbox. It is a board-level risk domain requiring measurable controls, auditing, and accountability.

In addition to these high-profile cases, the landscape of personal injury litigation has expanded to include emerging health concerns linked to popular medications. For instance, cases involving Mounjaro, Wegovy, Zepbound, and Trulicity have surfaced due to severe side effects such as vision loss or blindness associated with these drugs. These cases highlight the critical need for patient safety information and the importance of having experienced lawyers in these specific areas of medical litigation.

Opioids: Public Nuisance, Distribution Controls, and Compliance Failures

Opioid litigation reshaped contemporary thinking about distribution accountability, public nuisance theories, and the relationship between marketing, prescribing patterns, and community harm.

Key innovations and tensions

• Supply chain liability focus. Cases emphasized suspicious order monitoring, distribution controls, and the adequacy of diversion prevention systems.
• Novel legal theories under pressure. Public nuisance arguments, statutory consumer protection claims, and negligence theories were tested with varying success across jurisdictions.
• Settlement structures as remediation engines. Many resolutions emphasized abatement, funding earmarks, and oversight provisions.

From a governance standpoint, opioid litigation elevated expectations for compliance monitoring, risk escalation, and documented response protocols across regulated supply chains.

PFAS (“Forever Chemicals”): The Next-Generation Environmental Mass Tort

PFAS litigation is a defining modern mass tort because it combines environmental pathways, long latency, biomonitoring, and expanding regulatory attention.

What makes PFAS structurally different

• Ubiquity and exposure diversity. Plaintiffs allege harm through drinking water, industrial emissions, consumer products, and firefighting foams.
• Emerging science. Causation disputes often focus on dose, pathway attribution, and whether particular PFAS compounds are linked to specific outcomes.
• Remediation and monitoring claims. Many cases prioritize water treatment costs, medical monitoring, and property-related damages.

PFAS disputes reinforce a forward-looking compliance mandate: where chemicals persist, so does legal exposure. Sound corporate governance requires chemical inventory discipline, vendor oversight, product stewardship, and proactive environmental monitoring.

Roundup (Glyphosate): Jury Psychology, Scientific Narratives, and Bellwether Strategy

Roundup litigation emphasized how scientific controversy is translated for juries, and how a bellwether trial can drive negotiation leverage.

Enduring effects

• Scientific storytelling. Competing evaluations of carcinogenicity highlighted the difference between hazard identification and risk assessment, a distinction that often becomes decisive at trial.
• Punitive damages exposure. Verdicts underscored how corporate conduct evidence can escalate damages beyond compensatory ranges.
• Plaintiff inventory management. The litigation demonstrated how case screening, causation criteria, and settlement grids must be aligned early to prevent administrative overload.

The governance message is repetition with purpose: document what you knew, document what you did, and document why your decisions were reasonable under the information available at the time.

3M Combat Arms Earplugs: Government Contracting and Individualized Injury Proof

The earplug litigation showed how mass torts can scale even when each plaintiff’s injury is individualized, and how defense theories can turn on product use conditions and warnings.

Modern lessons

• Individual medical causation remains central. Hearing loss and tinnitus claims require careful audiology evidence and exposure history analysis.
• Contracting context matters. Procurement, specifications, and communications can shape warning duties and design arguments.
• Settlement architecture. Large inventories place premium value on transparent eligibility criteria and credible valuation methodology.

Why These Mass Torts Continue to Matter in 2026

The modern mass tort landscape is not simply “more cases.” It is more infrastructure.

• More data: plaintiff fact sheets, medical record digitization, exposure modeling, and analytics-based settlement valuation.
• More science: stricter demands for general causation proof and defensible expert methodology.
• More governance: elevated expectations for compliance systems, risk escalation, and board oversight of safety, quality, and marketing conduct.
• More procedural experimentation: streamlined discovery, coordinated state-federal efforts, and increased judicial management of inventories.

Mass torts reward proactive competence and penalize reactive improvisation. That is the central continuity across every era described above.

In addition to these significant cases like Roundup or 3M Combat Arms Earplugs, there are other ongoing litigation concerning medications such as Trulicity or Zepbound which have been reported to cause serious side effects including debilitating vision problems, macular edema or blurry vision. Such side effects have led to lawsuits against manufacturers for failing to adequately warn consumers about these risks. For instance, if someone suffered Zepbound vision problems as a result, they might consider pursuing a Zepbound vision loss lawsuit due to the severe consequences of such side effects.

Frequently Asked Questions

What is the difference between a mass tort and a class action?

A mass tort involves many individual cases tied to a common defendant, product, or event, but each plaintiff must generally prove individual causation and damages. A class action aggregates claims where common issues predominate and class-wide proof can resolve key elements for the group. For example, the Firefly Aerospace Class Action Lawsuit seeks to represent purchasers or acquirers of Firefly Aerospace Inc., showcasing how class actions can address widespread issues affecting many individuals.

What is an MDL, and why is it used in mass torts?

An MDL (multidistrict litigation) is a federal procedure that transfers related civil cases to one judge for coordinated pretrial proceedings. It is used to reduce duplicative discovery, manage expert litigation efficiently, and promote consistent rulings.

What is a bellwether trial?

A bellwether trial is a representative case selected for early trial to test liability and damages themes. Results can influence settlement negotiations, but bellwether outcomes do not automatically decide other plaintiffs’ cases.

Why is expert testimony so important in product and toxic exposure mass torts?

Because plaintiffs must typically establish general causation (the agent can cause the injury) and specific causation (it did cause the injury in this plaintiff). Those questions often require epidemiology, toxicology, medical differential etiology, and exposure assessment.

Do mass tort settlements pay everyone the same amount?

Usually not. Most mass tort settlements use matrices or grids that account for diagnosis, severity, age, exposure history, and other individualized factors. Documentation and eligibility criteria often determine award tiers.

For instance, in cases like the Baxter Class Action Lawsuit, settlements may vary significantly based on individual circumstances of each claimant.

Are PFAS lawsuits expected to expand further after 2026?

PFAS litigation is widely expected to continue expanding because exposures are widespread, regulatory standards are evolving, and remediation needs can be substantial. The pace and scope depend on scientific developments, enforcement trends, and discovery of contamination pathways.

What should companies learn from these mass torts?

They should treat safety, product stewardship, and compliance as measurable systems. The recurring lesson is repetition for emphasis: identify risks early, document decisions clearly, and implement controls consistently. Robust corporate governance reduces legal exposure and strengthens organizational integrity.